<DOC>
	<DOCNO>NCT02186418</DOCNO>
	<brief_summary>The purpose study determine whether transfer fetal hemoglobin gene use lentivirus vector ( gene transfer ) human blood making cell safe feasible patient sickle cell disease .</brief_summary>
	<brief_title>Gene Transfer Patients With Sickle Cell Disease</brief_title>
	<detailed_description>The purpose also determine kind gene transfer work get body make red blood cell n't sickle patient sickle cell disease .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Confirmed sickle cell disease severe Failed hydroxyurea therapy , unable tolerate hydroxyurea therapy , , 18 year age old , actively make choice take recommended daily hydroxyurea . Patients unable take hydroxyurea due financial safety monitoring constraint eligible . Lansky/Karnovsky performance scoreâ‰¥ 60 Ability undergo general regional ( spinal epidural ) anesthesia Adequate kidney , liver heart function determine clinical test Willing reside within 120 mile radius Cincinnati Children 's Hospital Medical Center period 36 month Active malignant disease Seropositive HIV Taken experimental drug past 30 day Abnormal pulmonary function test show severe obstruction , restriction diffusion defect Patients chronic transfusion : clinical stroke Pregnant breastfeeding Alpha thalassemia Cirrhosis liver , bridge hepatic fibrosis , active hepatitis Patients match sibling donor decline option hematopoietic stem cell transplant Confirmed pulmonary hypertension Any condition opinion investigator make participation ill advise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>hemoglobinopathy</keyword>
	<keyword>hematopoietic stem cell</keyword>
	<keyword>gene transfer</keyword>
	<keyword>gene therapy</keyword>
</DOC>